103 / 110
I
nduced
pluripotent
stem
cells
reprogramming
: E
pigenetics
and
applications
in
the
regenerative
medicine
R
ev
A
ssoc
M
ed
B
ras
2017; 63(2):180-189
189
62.
Zhong X, Li N, Liang S, Huang Q, Coukos G, Zhang L. Identification of
microRNAs regulating reprogramming factor LIN28 in embryonic stem
cells and cancer cells. J Biol Chem. 2010; 285(53):41961-71.
63. Choi YJ, Lin C, Ho JJ, He X, Okada N, Bu P, et al. miR-34 miRNAs provide a
barrier for somatic cell reprogramming. Nat Cell Biol. 2011; 13(11):1353-60.
64. Curry EL, Moad M, Robson CN, Heer R. Using induced pluripotent stem cells
as a tool for modelling carcinogenesis. World J Stem Cells. 2015; 7(2):461-9.
65. Takahashi K, Yamanaka S. A decade of transcription factor-mediated
reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016; 17(3):183-93.
66.
First iPS cell transplant patient makes progress one year on. The Japan
Times [internet]. 2015 [cited 23 May 2016]. Available from: http://www.
japantimes.co.jp/news/2015/10/02/national/science-health/first-ips-cell-transplant-patient-makes-progress-one-year#.WJxP59JVikq
67. Garber K. RIKEN suspends first clinical trial involving induced pluripotent
stem cells. Nat Biotechnol. 2015; 33(9):890-1.
68. Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic.
Nat Rev Mol Cell Biol. 2016; 17(3):194-200.
69. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling
and drug discovery. Nat Rev Mol Cell Biol. 2016; 17(3):170-82.
70.
Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA,
et al. Modelling pathogenesis and treatment of familial dysautonomia using
patient-specific iPSCs. Nature. 2009; 461(7262):402-6.
71. Wasik AM, Grabarek J, Pantovic A, Cie
ś
lar-Pobuda A, Asgari HR, Bundgaard-
Nielsen C, et al. Reprogramming and carcinogenesis – parallels and
distinctions. Int Rev Cell Mol Biol. 2014; 308:167-203.